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DAN FLOYD (Cell & Molecular Biology: Biochemistry)

Investigating the role of bS21 in vancomycin-resistant Staphylococcus
aureus
Sponsor: Kathryn Ramsey (Cell & Molecular Biology, Biomedical & Pharmaceutical
Sciences)

Staphylococcus aureus is a Gram-positive pathogenic bacterium commonly known for
being the causative organism of staph infections in clinical settings. In previous literature,
it has been observed that mutations in certain genes in S. aureus can result in resistance
to commonly used antibiotics. Specifically, mutations in the gene rpsU, encoding the
ribosomal protein bS21, have been present in strains of S. aureus resistant to the
antibiotic vancomycin. The aim of my project is to validate these findings by creating a
strain of S. aureus without bS21 and performing an antibiotic assay to determine the level
of resistance to vancomycin in this strain. To do this, I have been working to create a
plasmid that can be introduced into wild-type S. aureus and knock out the gene rpsU via
homologous recombination. To create the desired plasmid, I am modifying the pIMAY-Z
plasmid which contains the gene for chloramphenicol resistance; I began by amplifying
two desired sequences (also referred to as flanking regions) via PCR that will be inserted
into the plasmid. I then performed a restriction enzyme digest to cut the plasmid at the
insertion sites, along with cutting the amplified sequences at their ends so that they can
be added to the plasmid. I continued by performing a ligation to join the flanking regions
to the ends of the pIMAY-Z backbone and effectively “glue” the entire plasmid together. I
used this ligation to transform chemically competent IMO8B E. coli cells on Luria-Bertani
agar plates containing 25 ug/ml chloramphenicol, which amplified the desired plasmid for
use in further steps. Although I have not confirmed whether this plasmid has been
successfully produced through the digests, ligations, and transformations I have
performed so far, the positive and negative controls have been successful, and I am now
just waiting on official confirmation through sequencing.
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